Last reviewed: July 13, 2026
Last updated: July 13, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Tirzepatide has emerged as a powerful option for people struggling with weight management, activating both GLP-1 and GIP receptors to produce dual metabolic effects. Unlike single-action medications, tirzepatide influences two separate appetite-control and energy-burning pathways simultaneously. Understanding who qualifies for this treatment can help you determine if it aligns with your health goals.
Start your GLP-1 program with PlexusDx
One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.
Start your intake →
Basic Eligibility Requirements for Tirzepatide Treatment
PlexusDx evaluates candidacy based on established clinical criteria including body mass index (BMI), weight-related comorbidities, and overall health status. Most candidates fall into one of two categories: those with a BMI of 30 or higher, or those with a BMI between 27 and 29.9 paired with at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. A medical history assessment screens for contraindications and ensures the medication aligns with your current health profile.
Age requirements typically begin at 18 years old, with no upper age limit—though older adults may require additional cardiovascular screening. Pregnancy and breastfeeding are contraindications due to insufficient safety data in these populations. PlexusDx providers review medication interactions and past medication sensitivities to confirm tirzepatide is appropriate for your individual circumstances.
How Weight-Related Health Conditions Affect Your Qualification
Individuals with weight-related conditions qualify for tirzepatide even at lower BMI thresholds because these conditions indicate metabolic dysfunction warranting intervention. Common qualifying conditions include type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, and non-alcoholic fatty liver disease. Cardiovascular disease history or multiple risk factors also support tirzepatide candidacy, as clinical evidence shows weight reduction improves outcomes in these populations.
PlexusDx providers evaluate whether your specific health conditions create urgency for weight management intervention. Those with metabolic syndrome—a cluster of weight, blood pressure, and glucose abnormalities—typically benefit significantly from tirzepatide's dual-pathway mechanism. Even individuals with a single comorbidity but elevated BMI may qualify, as the medication addresses both the weight and the underlying metabolic driver.
The Role of Genetic Predisposition in Treatment Candidacy
PlexusDx offers the Precision Peptide Genetic Test to identify whether your genetic makeup predisposes you to respond favorably to tirzepatide or similar GLP-1 and GIP-agonist therapies. The test analyzes 14 peptide-pathway genes and 150+ genetic insights, including variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—markers that influence appetite sensitivity and metabolic rate. Certain genetic profiles suggest stronger responsiveness to tirzepatide's GIP pathway activation, making the test a valuable personalization tool.
Knowing your genetic predisposition helps PlexusDx providers tailor your treatment protocol and set realistic expectations for weight loss magnitude and timeline. Some individuals carry genetic variants associated with heightened appetite signaling or reduced energy expenditure, making them especially strong candidates for tirzepatide's dual-action approach. The $99 genetic test add-on (available after the first month of treatment) provides data-driven insights that refine your personalized protocol.
Medical History and Safety Screening for Tirzepatide Eligibility
PlexusDx requires a complete medication history and past treatment experience assessment before initiating tirzepatide, as certain interactions and contraindications must be ruled out. History of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia syndrome type 2, and severe pancreatitis are absolute contraindications. Providers also screen for gallbladder disease, kidney impairment, and vision problems (including diabetic retinopathy), as tirzepatide carries specific warnings for these conditions.
Your candidacy also depends on realistic expectations and commitment to lifestyle integration alongside medication use. PlexusDx evaluates whether you've attempted weight loss previously, understand that tirzepatide requires ongoing use to maintain results, and can tolerate potential gastrointestinal side effects during the initiation phase. Psychological readiness and absence of active eating disorders support successful treatment outcomes and strengthen your qualification profile.
Getting Started With PlexusDx: No Insurance Required, All 50 States
PlexusDx tirzepatide injection treatment is $289/mo month-to-month, or from $249/mo on the 6-month plan with a flat-rate pricing model—your dose may need to increase over time, but your price will not. The medication comes from licensed 503A compounding pharmacies, ensuring quality and customization for your specific protocol. Enrollment requires no insurance, no membership fees, and no long-term contracts; PlexusDx serves patients across all 50 states with HSA and FSA eligibility.
The qualification process starts with a brief online health assessment and consultation with a PlexusDx provider who reviews your medical history, current medications, and weight loss goals. Once approved, your first shipment arrives, and you begin with the microdose protocol before titrating upward based on tolerance and response. After your first month, you become eligible for the optional Precision Peptide Genetic Test to further personalize your long-term treatment approach.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need a BMI of 30 to qualify for tirzepatide with PlexusDx?
No—if you have a BMI between 27 and 29.9 plus at least one weight-related condition (diabetes, hypertension, sleep apnea), you qualify. PlexusDx evaluates the full clinical picture, not just BMI alone.
How does tirzepatide's dual-action mechanism make it different from other GLP-1 medications?
Tirzepatide activates both GLP-1 and GIP receptors, targeting two separate appetite and energy pathways simultaneously. Clinical trials show greater average weight loss with tirzepatide compared to single-action GLP-1 agonists like semaglutide.
What does the PlexusDx Precision Peptide Genetic Test reveal about my tirzepatide candidacy?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Are there medical conditions that disqualify me from tirzepatide?
Yes—personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe pancreatitis are absolute contraindications. PlexusDx screens for these and other conditions during the qualification review to ensure your safety.
Can I get tirzepatide from PlexusDx without insurance?
Yes—PlexusDx tirzepatide injection is available to all 50 states with no insurance requirement, no membership fees, and pricing at $289/mo month-to-month, or from $249/mo on the 6-month plan. Treatment is HSA and FSA eligible, providing flexible payment options.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Where to Buy Mounjaro: What You Need to Know About This Weight Loss Medication
When Do You Lose the Most Weight on Mounjaro?